Humanoid exosome composition with anti-oxidation effect as well as preparation method and application thereof

Abstract

The invention relates to a human-like exosome composition with an anti-oxidation effect as well as a preparation method and application of the human-like exosome composition, and belongs to the technical field of cosmetics and biology. The human-like exosome composition comprises a human-like exosome, a first active component and a solvent, the solvent comprises a first polyhydric alcohol; the first active component comprises rare ginsenoside CK and glabridin. The quasi-human-source exosome composition provided by the invention has good antioxidant activity, and the quasi-human-source exosome, the rare ginsenoside CK and the glabridin cooperate with one another, so that the antioxidant activity of the quasi-human-source exosome composition is greatly improved.

Description

Technical Field

[0001] This invention relates to the fields of cosmetics and biotechnology, specifically to a human-like exosome composition with antioxidant effects, its preparation method, and its application. Background Technology

[0002] Exosomes are nanoscale extracellular vesicles widely distributed in living organisms, typically ranging from 30 to 150 nm in diameter. They are secreted by various cell types, including human, animal, and plant cells. Natural exosomes play important roles in intercellular communication, immune regulation, tissue repair, and disease development by carrying bioactive molecules such as proteins, lipids, mRNA, and miRNA.

[0003] When skin is exposed to the external environment, it is easily affected by various factors such as ultraviolet radiation, air pollution, and electromagnetic radiation, leading to an excessive production of reactive oxygen species (ROS) in the body. When the rate of ROS production exceeds the body's own ability to eliminate them, it triggers an oxidative stress response, which in turn causes lipid peroxidation, protein denaturation, and DNA damage in skin cells. This manifests as dull skin, roughness, increased fine lines, decreased elasticity, and may even induce inflammation and pigmentation problems.

[0004] Therefore, developing cosmetic compositions with high antioxidant properties is of great significance for resisting oxidative damage, protecting the skin barrier, and delaying skin aging. Summary of the Invention

[0005] To address the aforementioned technical problems, the present invention provides the following technical solutions.

[0006] In a first aspect, the present invention provides a human-like exosome composition.

[0007] A human-like exosome composition, characterized in that the human-like exosome composition comprises: human-like exosomes, a first active ingredient, and a solvent; the solvent comprises a first polyol; the first active ingredient comprises rare ginsenoside CK and glycyrrhizin; The weight ratio of the human-like exosomes to the rare ginsenoside CK is 100:0.4~100:3. The weight ratio of the human-like exosomes to glycyrrhizin is 100:0.2 to 100:2.4; The weight ratio of glycyrrhizin to solvent is (0.2~2.4):(40~500).

[0008] In some embodiments, the human-like exosomes are prepared from a composition of hydrogenated lecithin, phytosphoprotein, cholesterol, ceramide, squalane, sodium stearoyl glutamate, surface-modified structure, second polyol, second active ingredient and water.

[0009] In some embodiments, the method for preparing human-like exosomes includes the following steps: (1) Preparation of alcohol phase: Hydrogenated lecithin, phytosphoprotein, cholesterol, ceramide, squalane, sodium stearoyl glutamate, surface-modified structure and second polyol are mixed to obtain alcohol phase; (2) Preparation of the aqueous phase: The second active ingredient is mixed with water to obtain the aqueous phase; (3) Preparation of mixed solution: Add the aqueous phase obtained in step (2) to the alcohol phase obtained in step (1), stir, homogenize, and obtain a mixed solution; (4) Ultrasonic, high-pressure homogenization or extrusion membrane treatment: The mixed solution obtained in step (3) is subjected to ultrasonic, high-pressure homogenization or extrusion membrane treatment to obtain the human-like exosomes; The surface-modified structure includes a targeting peptide; the targeting peptide includes cyclotetrapeptide-24-aminocyclohexanecarboxylate. The weight ratio of hydrogenated lecithin to phytosphingosine is (3-7): (0.03-0.1); The weight ratio of hydrogenated lecithin to cholesterol is (3-7): (0.3-1); The weight ratio of hydrogenated lecithin to ceramide is (3-7): (0.005-0.04); The weight ratio of the hydrogenated lecithin to squalane is (3-7): (0.05-0.2); The weight ratio of hydrogenated lecithin to sodium stearoyl glutamate is (3-7): (0.2-0.8); The weight ratio of the hydrogenated lecithin to the second polyol is (3-7):(7-30). The weight ratio of the hydrogenated lecithin to the surface-modified structure is (3-7): (0.001-0.05); The weight ratio of the second polyol to the water is (7-30): (19.2-85.1); The weight ratio of the second active ingredient to water is (0.61-51.52): (19.2-85.1).

[0010] In some embodiments, the method for preparing the human-like exosome composition includes: Rare ginsenoside CK and glycyrrhizin are mixed with the solvent to obtain mixture A. Mixture A is then mixed with the human-like exosomes to obtain the human-like exosome composition.

[0011] Rare ginsenoside CK: Its structural formula is: .

[0012] Glabridin: Its English name is Glabridin, and its CAS number is 59870-68-7.

[0013] In some embodiments, the weight ratio of the human-like exosomes to rare ginsenoside CK is 100:0.4 to 100:3. In some embodiments, the weight ratio of the human-like exosomes to rare ginsenoside CK is 100:0.4, 100:0.5, 100:1, 100:1.4, 100:1.5, 100:2, 100:2.5, 100:3, or any value within the range of any two of these values.

[0014] In some embodiments, the weight ratio of the human-like exosomes to glycyrrhizin is 100:0.2 to 100:2.4. In some embodiments, the weight ratio of the human-like exosomes to glycyrrhizin is 100:0.2, 100:0.5, 100:0.6, 100:0.7, 100:0.8, 100:0.9, 100:1, 100:1.5, 100:1.6, 100:1.7, 100:1.8, 100:1.9, 100:2, 100:2.1, 100:2.2, 100:2.3, 100:2.4, or any value within the range of any two of these values.

[0015] In some embodiments, the weight ratio of glycyrrhizin to solvent is (0.2~2.4):(40~500). In some embodiments, the weight ratio of glycyrrhizin to solvent is 0.8:60~1:500. In some embodiments, the weight ratio of glycyrrhizin to solvent is 0.8:60, 2:200, 1.6:200, or 2.4:300, 0.2:40, 0.7:60, 0.6:60, 0.5:60, 0.4:60, 0.3:60, 0.2:60, 1:500, or any value within the range of any two of these values.

[0016] In some embodiments, the weight ratio of hydrogenated lecithin to phytosphingosine is 7:0.1 to 4:0.03. In some embodiments, the weight ratio of hydrogenated lecithin to phytosphingosine is 7:0.1, 5:0.05, 3:0.03, or 4:0.03.

[0017] In some embodiments, the weight ratio of hydrogenated lecithin to cholesterol is 3:0.6-4:0.3. In some embodiments, the weight ratio of hydrogenated lecithin to cholesterol is 3:0.6, 5:0.8, 7:1, 4:0.4, or 4:0.3.

[0018] In some embodiments, the weight ratio of hydrogenated lecithin to ceramide is 3:0.02 to 3:0.005. In some embodiments, the weight ratio of hydrogenated lecithin to ceramide is 5:0.03, 3:0.02, 7:0.04, 4:0.01, or 3:0.005.

[0019] In some embodiments, the weight ratio of hydrogenated lecithin to squalane is 7:0.2 to 3:0.05. In some embodiments, the weight ratio of hydrogenated lecithin to squalane is 7:0.2, 5:0.1, or 3:0.05.

[0020] In some embodiments, the weight ratio of hydrogenated lecithin to sodium stearoyl glutamate is 3:0.6 to 5:0.2. In some embodiments, the weight ratio of hydrogenated lecithin to sodium stearoyl glutamate is 3:0.6, 7:0.8, 4:0.4, or 5:0.2.

[0021] In some embodiments, the weight ratio of hydrogenated lecithin to the second polyol is 3:30 to 5:7. In some embodiments, the weight ratio of hydrogenated lecithin to the second polyol is 3:30, 4:15, 3:10, 7:20, or 5:7.

[0022] In some embodiments, the weight ratio of the hydrogenated lecithin to the surface-modified structure is 7:0.05 to 3:0.001. In some embodiments, the weight ratio of the hydrogenated lecithin to the surface-modified structure is 7:0.05, 5:0.01, 4:0.002, or 3:0.001.

[0023] In some embodiments, the weight ratio of the second polyol to the water is 10:85.0 to 20:19.2. In some embodiments, the weight ratio of the second polyol to the water is 10:85.0885 to 20:19.2905. In some embodiments, the weight ratio of the second polyol to the water is 10:85.0885, 7:55.594, 7:45.609, 15:79.327, 15:59.966, 30:39.9585, or 20:19.2905.

[0024] In some embodiments, the weight ratio of the second active ingredient to water is 0.61:85.0~51.5:19.2. In some embodiments, the weight ratio of the second active ingredient to water is 0.6105:85.0885~51.5195:19.2905. In some embodiments, the weight ratio of the second active ingredient to water is 0.6105:85.0885, 0.751:79.327, 20.212:59.966, 25.7555:39.9585, 31.216:55.594, 41.201:45.609, or 51.5195:19.2905.

[0025] In some embodiments, the second active ingredient includes at least one of arginine / lysine peptide solution, PDRN, miRNA, mixed amino acids, and nicotinamide adenine dinucleotide.

[0026] In some embodiments, the mixed amino acids include at least one selected from alanine, histidine hydrochloride, arginine, serine, proline, glutamic acid, threonine, valine, leucine, isoleucine, glycine, phenylalanine, taurine, and allantoin. In some embodiments, the mixed amino acids include alanine, histidine hydrochloride, arginine, serine, proline, glutamic acid, threonine, valine, leucine, isoleucine, glycine, phenylalanine, taurine, and allantoin. In some embodiments, the mixed amino acids include alanine, histidine hydrochloride, arginine, serine, proline, glutamic acid, threonine, valine, leucine, isoleucine, glycine, phenylalanine, taurine, and allantoin, and the components are mixed in equal weight ratios.

[0027] In some embodiments, the first polyol and the second polyol are each independently selected from at least one of 1,3-butanediol, 1,3-propanediol, glycerol, 1,2-hexanediol, and ethoxydiethylene glycol.

[0028] In some embodiments, the content of hydrogenated lecithin is 3 wt%-7 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of hydrogenated lecithin is 3 wt%, 4 wt%, 5 wt%, 6 wt%, or 7 wt% based on the total weight of the human-like exosomes.

[0029] In some embodiments, the content of phytosphingosine is 0.03 wt%-0.1 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of phytosphingosine is 0.03 wt%, 0.04 wt%, 0.05 wt%, 0.06 wt%, 0.07 wt%, 0.08 wt%, 0.09 wt%, or 0.1 wt% based on the total weight of the human-like exosomes.

[0030] In some embodiments, the cholesterol content is 0.3 wt%-1 wt% based on the total weight of the human-like exosomes. In some embodiments, the cholesterol content is 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, 0.8 wt%, 0.9 wt%, or 1 wt% based on the total weight of the human-like exosomes.

[0031] In some embodiments, the content of the ceramide is 0.005 wt%-0.04 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of the ceramide is 0.005 wt%, 0.01 wt%, 0.02 wt%, 0.03 wt%, or 0.04 wt% based on the total weight of the human-like exosomes.

[0032] In some embodiments, the squalane content is 0.05 wt%-0.2 wt% based on the total weight of the human-like exosomes. In some embodiments, the squalane content is 0.05 wt%, 0.06 wt%, 0.07 wt%, 0.08 wt%, 0.09 wt%, 0.1 wt%, 0.15 wt%, or 0.2 wt% based on the total weight of the human-like exosomes.

[0033] In some embodiments, the content of sodium stearoyl glutamate is 0.2 wt%-0.8 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of sodium stearoyl glutamate is 0.2 wt%, 0.3 wt%, 0.4 wt%, 0.5 wt%, 0.6 wt%, 0.7 wt%, or 0.8 wt% based on the total weight of the human-like exosomes.

[0034] In some embodiments, the content of the second polyol is 7 wt%-30 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of the second polyol is 7 wt%, 8 wt%, 9 wt%, 10 wt%, 11 wt%, 12 wt%, 13 wt%, 14 wt%, 15 wt%, 16 wt%, 17 wt%, 18 wt%, 19 wt%, 20 wt%, 21 wt%, 22 wt%, 23 wt%, 24 wt%, 25 wt%, 26 wt%, 27 wt%, 28 wt%, 29 wt%, or 30 wt% based on the total weight of the human-like exosomes.

[0035] In some embodiments, the content of the surface-modified structure is 0.001 wt%-0.05 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of the surface-modified structure is 0.001 wt%, 0.002 wt%, 0.003 wt%, 0.004 wt%, 0.005 wt%, 0.006 wt%, 0.007 wt%, 0.008 wt%, 0.009 wt%, 0.01 wt%, 0.015 wt%, 0.02 wt%, 0.025 wt%, 0.03 wt%, 0.035 wt%, 0.04 wt%, 0.045 wt%, or 0.05 wt% based on the total weight of the human-like exosomes.

[0036] In some embodiments, the content of the second active ingredient is 0.61 wt%-51.52 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of the second active ingredient, calculated based on the total weight of the human-like exosomes, is 0.61 wt%, 0.65 wt%, 0.70 wt%, 0.75 wt%, 0.751 wt%, 1 wt%, 1.5 wt%, 1.6 wt%, 0.6105 wt%, 2 wt%, 3 wt%, 4 wt%, 5 wt%, 10 wt%, 15 wt%, 20 wt%, 21 wt%, 21.2 wt%, 20.212 wt%, 22 wt%, 23 wt%, 24 wt%, 25 wt%, 26 wt%, 25.7555 wt%, 27 wt%, 28 wt%, 29 wt%, 30 wt%, 31 wt%, 32 wt%, 31.216 wt%, 33 wt%, 34 wt%, 35 wt%, 40 wt%, 41 wt%, 41.201 wt%, 42 wt%, 43 wt%, 44 wt%, 45 wt%, 50 wt%, 51 wt%, 51.5195wt% or 51.52wt%.

[0037] In some embodiments, the water content is 19.2 wt% to 85.1 wt% based on the total weight of the human-like exosomes. In some embodiments, the water content, calculated based on the total weight of the humanoid exosomes, is 19.2 wt%, 19.2905 wt%, 19.5 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 39 wt%, 39.9585 wt%, 40 wt%, 45 wt%, 45.5 wt%, 45.609 wt%, 50 wt%, 54 wt%, 55.594 wt%, 55 wt%, 56 wt%, 57 wt%, 58 wt%, 58.5 wt%, 59.966 wt%, 60 wt%, 65 wt%, 70 wt%, 75 wt%, 79 wt%, 79.5 wt%, 79.327 wt%, 80 wt%, 81 wt%, 82 wt%, 83 wt%, 84 wt%, 85.0885 wt%, or 85.1 wt%.

[0038] In some embodiments, the content of the arginine / lysine peptide solution is 0-50 wt%, calculated based on the total weight of the human-like exosomes. In some embodiments, the content of the arginine / lysine peptide solution is 0 wt%, 5 wt%, 10 wt%, 15 wt%, 20 wt%, 25 wt%, 30 wt%, 35 wt%, 40 wt%, 45 wt%, or 50 wt%, calculated based on the total weight of the human-like exosomes.

[0039] In some embodiments, the PDRN content is 0-1 wt% based on the total weight of the human-like exosomes. In some embodiments, the PDRN content is 0.1 wt%-1 wt% based on the total weight of the human-like exosomes. In some embodiments, the PDRN content is 0.1 wt%, 0.5 wt%, or 1 wt% based on the total weight of the human-like exosomes.

[0040] In some embodiments, the miRNA content is 0 wt% to 0.002 wt% based on the total weight of the human-like exosomes. In some embodiments, the miRNA content is 0.0005 wt% to 0.002 wt% based on the total weight of the human-like exosomes. In some embodiments, the miRNA content is 0.0005 wt%, 0.001 wt%, 0.0015 wt%, or 0.002 wt% based on the total weight of the human-like exosomes.

[0041] In some embodiments, the content of the mixed amino acids, calculated based on the total weight of the human-like exosomes, is 0 wt% to 0.018 wt%. In some embodiments, the content of the mixed amino acids, calculated based on the total weight of the human-like exosomes, is 0 wt%, 0.005 wt%, 0.01 wt%, 0.015 wt%, 0.016 wt%, 0.017 wt%, or 0.018 wt%.

[0042] In some embodiments, the content of nicotinamide adenine dinucleotide (NADP) is 0.1 wt% to 0.5 wt% based on the total weight of the human-like exosomes. In some embodiments, the content of NADP is 0.1 wt%, 0.125 wt%, 0.15 wt%, 0.2 wt%, 0.25 wt%, 0.3 wt%, 0.35 wt%, 0.4 wt%, 0.45 wt%, or 0.5 wt% based on the total weight of the human-like exosomes.

[0043] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 3wt%-7wt%, the content of phytosphingosine is 0.03wt%-0.1wt%, the content of cholesterol is 0.3wt%-1wt%, the content of ceramide is 0.005wt%-0.04wt%, the content of squalane is 0.05wt%-0.2wt%, the content of sodium stearoyl glutamate is 0.2wt%-0.8wt%, the content of the second polyol is 7wt%-30wt%, the content of the surface-modified structure is 0.001wt%-0.05wt%, the content of the second active ingredient is 0.61wt%-51.52wt%, and the content of water is 19.2wt%-85.1wt%.

[0044] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 3wt%-7wt%, the content of phytosphingosine is 0.03wt%-0.1wt%, the content of cholesterol is 0.3wt%-1wt%, the content of ceramide is 0.005wt%-0.04wt%, the content of squalane is 0.05wt%-0.2wt%, the content of sodium stearoyl glutamate is 0.2wt%-0.8wt%, the content of the second polyol is 7wt%-30wt%, the content of the surface-modified structure is 0.001wt%-0.05wt%, the content of the second active ingredient is 0.61wt%-51.52wt%, and the balance is water.

[0045] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 3wt%-7wt%, the content of phytosphingosine is 0.03wt%-0.1wt%, the content of cholesterol is 0.3wt%-1wt%, the content of ceramide is 0.005wt%-0.04wt%, the content of squalane is 0.05wt%-0.2wt%, the content of sodium stearoyl glutamate is 0.2wt%-0.8wt%, the content of the second polyol is 7wt%-30wt%, the content of the surface-modified structure is 0.001wt%-0.05wt%, the content of the second active ingredient is 0.6105wt%-51.5195wt%, and the balance is water.

[0046] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 4 wt%, the content of phytosphingosine is 0.03 wt%, the content of cholesterol is 0.3 wt%, the content of ceramide is 0.01 wt%, the content of squalane is 0.08 wt%, the content of sodium stearoyl glutamate is 0.4 wt%, the content of the second polyol is 15 wt%, the content of the surface-modified structure is 0.002 wt%, the content of the second active ingredient is 20.212 wt%, and the balance is water.

[0047] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 3 wt%, the content of phytosphingosine is 0.03 wt%, the content of cholesterol is 0.6 wt%, the content of ceramide is 0.005 wt%, the content of squalane is 0.05 wt%, the content of sodium stearoyl glutamate is 0.6 wt%, the content of the second polyol is 30 wt%, the content of the surface-modified structure is 0.001 wt%, the content of the second active ingredient is 25.7555 wt%, and the balance is water.

[0048] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 5 wt%, the content of phytosphingosine is 0.05 wt%, the content of cholesterol is 0.8 wt%, the content of ceramide is 0.03 wt%, the content of squalane is 0.1 wt%, the content of sodium stearoyl glutamate is 0.2 wt%, the content of the second polyol is 7 wt%, the content of the surface-modified structure is 0.01 wt%, the content of the second active ingredient is 31.216 wt%, and the balance is water.

[0049] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 7 wt%, the content of phytosphingosine is 0.1 wt%, the content of cholesterol is 1 wt%, the content of ceramide is 0.04 wt%, the content of squalane is 0.2 wt%, the content of sodium stearoyl glutamate is 0.8 wt%, the content of the second polyol is 20 wt%, the content of the surface-modified structure is 0.05 wt%, the content of the second active ingredient is 51.5195 wt%, and the balance is water.

[0050] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 4 wt%, the content of phytosphingosine is 0.03 wt%, the content of cholesterol is 0.4 wt%, the content of ceramide is 0.01 wt%, the content of squalane is 0.08 wt%, the content of sodium stearoyl glutamate is 0.4 wt%, the content of the second polyol is 15 wt%, the content of the surface-modified structure is 0.002 wt%, the content of the second active ingredient is 0.751 wt%, and the balance is water.

[0051] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 3 wt%, the content of phytosphingosine is 0.03 wt%, the content of cholesterol is 0.6 wt%, the content of ceramide is 0.02 wt%, the content of squalane is 0.05 wt%, the content of sodium stearoyl glutamate is 0.6 wt%, the content of the second polyol is 10 wt%, the content of the surface-modified structure is 0.001 wt%, the content of the second active ingredient is 0.6105 wt%, and the balance is water.

[0052] In some embodiments, based on the total weight of the human-like exosomes, the content of hydrogenated lecithin is 5 wt%, the content of phytosphingosine is 0.05 wt%, the content of cholesterol is 0.8 wt%, the content of ceramide is 0.03 wt%, the content of squalane is 0.1 wt%, the content of sodium stearoyl glutamate is 0.2 wt%, the content of the second polyol is 7 wt%, the content of the surface-modified structure is 0.01 wt%, the content of the second active ingredient is 41.201 wt%, and the balance is water.

[0053] In some embodiments, the pressure of high-pressure homogenization in step (4) is 1500 bar to 2000 bar. In some embodiments, the pressure of high-pressure homogenization in step (4) is 1500 bar, 1600 bar, 1700 bar, 1800 bar, 1900 bar or 2000 bar.

[0054] In some embodiments, the high-pressure homogenization in step (4) is repeated 4-6 times. In some embodiments, the high-pressure homogenization in step (4) is repeated 4 times, 5 times, or 6 times.

[0055] In some embodiments, the high-pressure homogenization temperature in step (4) is 10°C-25°C. In some embodiments, the high-pressure homogenization temperature in step (4) is 10°C, 15°C, 20°C or 25°C.

[0056] Secondly, the present invention provides a method for preparing the aforementioned human-like exosome composition.

[0057] A method for preparing a human-like exosome composition according to the first aspect, comprising: mixing rare ginsenoside CK and glycyrrhizin with the solvent to obtain a mixture A, and then mixing the mixture A with the human-like exosomes to obtain the human-like exosome composition.

[0058] Thirdly, the present invention provides an application of the aforementioned human-like exosome composition or the human-like exosome composition prepared by the aforementioned preparation method.

[0059] The use of a human-like exosome composition as described in the first aspect or a human-like exosome composition prepared by the preparation method described in the second aspect in the preparation of cosmetics.

[0060] In some embodiments, the cosmetic is used for antioxidant purposes.

[0061] In some embodiments, the dosage forms of the cosmetics include aqueous solutions, serums, lotions, creams, gels, ointments, oils, powders, aerosols, sprays, masks, eye creams, lyophilized preparations, or nano-preparations.

[0062] Fourthly, the present invention provides a cosmetic product.

[0063] A cosmetic product comprising the human-like exosome composition described in the first aspect or the human-like exosome composition prepared by the preparation method described in the second aspect.

[0064] In some embodiments, the cosmetic is used for antioxidant purposes.

[0065] In some embodiments, the dosage forms of the cosmetics include aqueous solutions, serums, lotions, creams, gels, ointments, oils, powders, aerosols, sprays, masks, eye creams, lyophilized preparations, or nano-preparations.

[0066] Beneficial effects Compared with the prior art, at least one of the following beneficial effects is present in a certain embodiment of the present invention: (1) The human-like exosome composition provided by the present invention has excellent DPPH free radical scavenging activity and ROS inhibition rate, and has excellent antioxidant properties.

[0067] (2) Compared with one or two of human-like exosomes, rare ginsenoside CK and glycyrrhizin, the human-like exosome composition provided by the present invention contains human-like exosomes, rare ginsenoside CK and glycyrrhizin at the same time. When the three are present at the same time, they have a synergistic effect on antioxidant properties, which has an unexpected synergistic effect.

[0068] (3) Compared with one or two of human-like exosomes, rare ginsenoside CK and glycyrrhizin, the human-like exosome composition provided by the present invention contains human-like exosomes, rare ginsenoside CK and glycyrrhizin at the same time. When the three are present at the same time, they synergistically enhance each other, greatly improve the stability of the antioxidant properties of the obtained human-like exosome composition, and have unexpected synergistic effects.

[0069] (4) Compared with other active ingredients (such as ginsenoside Rg3 or retinol), the present invention preferably uses rare ginsenoside CK, which is more conducive to improving the antioxidant properties and stability of the obtained human-like exosome composition, and has unexpected technical effects.

[0070] (5) Compared with other active ingredients (such as resveratrol or glutathione), the present invention preferably uses glycyrrhizin, which is more conducive to improving the antioxidant properties and stability of the obtained human-like exosome composition, and has unexpected technical effects.

[0071] Terminology Explanation In the description of this invention, "a plurality of" means two or more, unless otherwise explicitly specified.

[0072] The terms “room temperature” or “normal temperature” refer to ambient temperature, which is approximately 10°C to approximately 35°C, approximately 10°C to approximately 30°C, or approximately 20°C to 30°C, or approximately 25°C.

[0073] The term "wt%" indicates a weight percentage.

[0074] The term "rpm" stands for the unit of rotational speed, "revolutions per minute".

[0075] The term "v / v" indicates a volume ratio.

[0076] The term "parts by weight" refers to a dimensionless unit that represents the relative weight ratio between components. Its core function is to clearly define the "relative dosage relationship" of different ingredients in a formula, rather than specifying specific absolute weights (such as grams or kilograms).

[0077] The term "human-like exosome" refers to a type of nanovesicle with a lipid bilayer membrane structure manufactured through non-biosynthetic pathways (such as self-assembly, template method, microfluidic technology, cell membrane biomimicry, etc.). The resulting nanovesicles possess the same or similar key physicochemical properties (such as size, morphology, membrane structure) and biological functions (such as efficient drug delivery, cell targeting, and crossing biological barriers) as natural human exosomes. The physicochemical properties of the resulting nanovesicles may be the same as or not completely identical to those of natural human exosomes, with the aim of selectively mimicking their key properties to achieve similar application goals (such as targeted delivery, immune escape, biocompatibility, etc.).

[0078] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0079] In the following content, all figures disclosed herein, whether or not they use the words "approximately" or "about," are approximate values. The value of each figure may vary by 1%, 2%, 5%, 7%, 8%, 10%, 15%, or 20%. Whenever a figure with a value of N is disclosed, any figure with a value of N+ / -1%, N+ / -2%, N+ / -3%, N+ / -5%, N+ / -7%, N+ / -8%, N+ / -10%, N+ / -15%, or N+ / -20% will be explicitly disclosed, where "+ / -" indicates addition or subtraction. Detailed Implementation

[0080] To enable those skilled in the art to better understand the technical solutions of the present invention, some non-limiting embodiments are further disclosed below to provide a more detailed description of the present invention.

[0081] All reagents used in this invention can be purchased commercially or prepared by the methods described in this invention.

[0082] I. The sources of some of the reagents used in the various embodiments or comparative examples of this invention are as follows: (1) Arginine / Lysine peptide solution: Trade name: EPITENSIVE™ EVO; Manufacturer: LipoTrueScience & Biotechnologies.

[0083] (2) PDRN: INCI name: DNA sodium; Catalogue of used chemical raw materials (2021 edition) No.: 00383; Trade name: PDRN-C; Manufacturer: Shanghai Huiwen Biotechnology Co., Ltd.

[0084] (3) miRNA: Trade name: miRITA-129™; Manufacturer: Xi'an Ailingke Biotechnology Co., Ltd.

[0085] (4) Mixed amino acids: Alanine, histidine hydrochloride, arginine, serine, proline, glutamic acid, threonine, valine, leucine, isoleucine, glycine, phenylalanine, taurine and allantoin are mixed in equal weight ratio to obtain mixed amino acids.

[0086] (5) Nicotinamide adenine dinucleotide: CAS number 53-84-9.

[0087] (6) Cyclotetrapeptide-24-aminocyclohexane carbamate: Shenzhen Vikitech Co., Ltd.

[0088] Examples 1-4: Human-like exosome compositions 1. Formula: See Table 1.

[0089] Table 1: Formulation of Human-like Exosome Compositions

[0090] 2. Method for preparing human-like exosomes: (1) Preparation of alcohol phase: Hydrogenated lecithin, phytosphoprotein, cholesterol, ceramide, squalane, sodium stearoyl glutamate, surface-modified structure and second polyol are mixed to obtain alcohol phase; (2) Preparation of the aqueous phase: The second active ingredient is mixed with water to obtain the aqueous phase; (3) Preparation of mixed solution: Add the aqueous phase obtained in step (2) to the alcohol phase obtained in step (1), stir, homogenize, and obtain a mixed solution; (4) High pressure homogenization: The mixed solution obtained in step (3) is subjected to high pressure homogenization (pressure 1500 bar, 4 cycles, temperature controlled at 25°C) to obtain the human-like exosomes.

[0091] 3. Preparation method of human-like exosome composition: Rare ginsenoside CK and glycyrrhizin are mixed with the first polyol to obtain mixture A. Mixture A is then mixed with the human-like exosomes to obtain the human-like exosome composition.

[0092] Example 5: Investigation of High-Pressure Homogeneous Pressure Conditions Example 5: The only difference from Example 1 is that the high-pressure homogenization pressure is adjusted to 2000 bar, and the other conditions are the same as in Example 1.

[0093] Example 6: Investigation of the Number of High-Pressure Homogenization Cycles Example 6: The only difference from Example 1 is that the number of high-pressure homogenization cycles is adjusted to 6, and the other conditions are the same as in Example 1.

[0094] Examples 7-9: Human-like exosome compositions Formula: See Table 2.

[0095] Table 2: Formulations of Human Exosome Compositions in Examples 7-9

[0096] Preparation method: The difference from the preparation method of Examples 1-4 is that the temperature of high pressure homogenization in step (4) is adjusted to 10℃~20℃ (10℃ in Example 7, 15℃ in Example 8, and 20℃ in Example 9). In addition, if the weight part of a certain component is 0, it is not added in the preparation method. The other conditions are the same as the preparation methods of Examples 1-4.

[0097] Comparative Examples 1-3: Investigation of Single Active Ingredients Comparative Example 1: The only difference from Example 1 is that rare ginsenoside CK and glycyrrhizin are not added, and the other conditions are the same as in Example 1.

[0098] Comparative Example 2: The only difference from Example 1 is that human-derived exosomes and glycyrrhizin are not added, while the other conditions are the same as in Example 1.

[0099] Comparative Example 3: The only difference from Example 1 is that human-like exosomes and rare ginsenoside CK are not added; all other conditions are the same as in Example 1.

[0100] Comparative Examples 4-6: Investigation of Dual Active Ingredients Comparative Example 4: The only difference from Example 1 is that glycyrrhizin was not added, and the other conditions are the same as in Example 1.

[0101] Comparative Example 5: The only difference from Example 1 is that rare ginsenoside CK is not added; all other conditions are the same as in Example 1.

[0102] Comparative Example 6: The only difference from Example 1 is that no human-derived exosomes are added; all other conditions are the same as in Example 1.

[0103] Comparative Examples 7-8: Substitution Investigation of Rare Ginsenoside CK Comparative Example 7: The only difference from Example 1 is that rare ginsenoside CK is replaced with ginsenoside Rg3 (CAS No. 14197-60-5), and the other conditions are the same as in Example 1.

[0104] Comparative Example 8: The only difference from Example 1 is that rare ginsenoside CK is replaced with retinol (CAS No. 68-26-8), and the other conditions are the same as in Example 1.

[0105] Comparative Examples 9-10: An Investigation into the Substitution of Glycyrrhizin Comparative Example 9: The only difference from Example 1 is that glycyrrhizin was replaced with resveratrol (CAS No. 501-36-0), and the other conditions are the same as in Example 1.

[0106] Comparative Example 10: The only difference from Example 1 is that glycyrrhizin was replaced with glutathione (CAS No. 70-18-8), and the other conditions are the same as in Example 1.

[0107] Example 10: Preparation of Aqueous Essence Formula: See Table 3.

[0108] Table 3:

[0109] Preparation method: 1. Heat water to 85°C, add p-hydroxyacetophenone and three-fifths of the formula amount of 1,3-butanediol and stir until fully dissolved, then cool to below 60°C (e.g., 50°C) to obtain phase A; 2. After premixing the remaining amount of 1,3-butanediol with transparent xanthan gum, stir and add it to phase A at a temperature below 60°C (e.g., 50°C). Stir until fully swollen, free of fish-eye particles, and thoroughly homogenized. Continue to cool to a temperature below 40°C (e.g., 35°C) to obtain phase B. 3. Add the human-like exosome composition and 1,2-pentanediol to phase B at a temperature below 40℃ (e.g., 35℃), stir thoroughly, and then add water until the total content of all components is 100wt% to obtain the water-based essence product.

[0110] The human-like exosome compositions of different embodiments were used to prepare corresponding aqueous essence products according to the above operation.

[0111] Experimental Example 1: Cytotoxicity Test The cytotoxic effects of human epidermal cells (HaCaT) obtained in each example on human skin cells were detected using this method. Normally cultured and stable cells were digested, counted, and seeded into 96-well plates (10,000 cells per well). After 24 hours, a monolayer formed. Culture medium containing different concentrations of the test substance was added, and the cells were cultured for another 48 hours. Afterward, the cells were treated with a CCK-8 assay kit, and the absorbance (OD) at 450 nm was measured using a microplate reader. Human epidermal cells (HaCaT) cultured in medium without the test substance for 48 hours served as a negative control. Relative cell viability was calculated using the following formula.

[0112] Relative cell viability = (Sample group OD value - Background OD value) / (Negative control OD value - Background OD value) × 100% The results are shown in Table 4.

[0113] Table 4: Relative Cell Viability

[0114] Conclusion: The relative activity of the sample group was higher than that of the negative control, indicating that the human-like exosome composition provided by the present invention has good safety.

[0115] Experimental Example 2: Antioxidant Efficacy Assessment - DPPH Free Radical Scavenging Test Method The cosmetic compositions of the above examples and comparative examples were sealed and placed at 45℃±2℃ / 75%RH for 0 days and 1 month, respectively, and the DPPH free radical scavenging rate was tested according to the following methods.

[0116] 1. Principle 1,1-Diphenyl-2-trinitrophenylhydrazine (DPPH) is a stable, long-lived free radical. Its ethanol solution is deep purple and exhibits strong absorption around 517 nm. In the presence of a free radical scavenger, the light absorption of the DPPH ethanol solution is reduced due to the pairing of its unpaired electrons. The degree of fading of the DPPH ethanol solution is linearly related to the number of electrons it accepts. This can be used to evaluate the ability of a test sample to scavenge free radicals, i.e., the magnitude of its antioxidant activity.

[0117] 2. Equipment Analyze the balance scale; pipette; ELISA reader.

[0118] 3. Reagents (1) 95% ethanol: Dissolve ethanol in water until the volume percentage of ethanol is 95%; (2) 1,1-Diphenyl-2-trinitrophenylhydrazine (DPPH); (3) 0.12 mg / mL DPPH ethanol solution: Weigh 12 mg of 1,1-diphenyl-2-trinitrophenylhydrazine into a 250 mL beaker, add 100 mL of 95% ethanol, and sonicate to dissolve for 30 min. Store in the dark at 4 degrees Celsius and use within 24 hours.

[0119] (4) Positive control: Vitamin E, purity ≥96%.

[0120] 4. Test methods (1) Preliminary experiment: Take 1 mL of DPPH solution, add a small amount of sample solution to it, add slowly and gradually while mixing, and observe the fading of the solution. When the solution color has basically faded, record the amount of sample added. The concentration corresponding to this amount of sample added is the maximum concentration of the sample. Based on this concentration, set a total of 7 concentration gradients to the lower level, which will be used as the concentration gradient of the sample in the formal experiment.

[0121] (2) The positive control was dissolved and diluted with 95% ethanol to prepare a series of concentration gradients of 0.1 mg / mL, 0.08 mg / mL, 0.06 mg / mL, 0.04 mg / mL, 0.02 mg / mL and 0.01 mg / mL to verify the test system.

[0122] (3) Test substance preparation: Water-soluble test substances are diluted with water to prepare multi-level concentration gradient samples, and oil-soluble test substances are diluted with 95% ethanol to prepare multi-level concentration gradient samples.

[0123] (4) Referring to Table 5, set up sample reaction wells (T), sample background wells (T0), solvent reaction wells (C), solvent background wells (C0), positive control wells (P), and positive control background wells (P0) in a 96-well microplate. Each reaction well (T, C, P) should have 3 parallel wells.

[0124] (5) Add 50 μL of sample solution to the sample reaction well (T) and sample background well (T0). Add 50 μL of vitamin E solution to the positive control well (P) and positive control background well (P0). Add 50 μL of sample solvent to the solvent reaction well (C) and solvent background well (C0). Then add 100 μL of solvent (water or 95% ethanol) to each well, for a total of 150 μL.

[0125] (6) Add 50 μL of DPPH ethanol solution to the sample reaction wells (T), solvent reaction wells (C), and positive control wells (P). Replace the sample background wells (T0), solvent background wells (C0), and positive control background wells (P0) with 50 μL of 95% ethanol. Shake gently and let stand at room temperature in the dark for 10 minutes. Transfer the ELISA plate to the microplate reader and measure the absorbance at 517 nm.

[0126] Table 5: Sample Addition Requirements

[0127] 5 Result Calculation (1) Calculate the DPPH radical scavenging rate: ……………………………(1) In the formula: T—Absorbance of the sample reaction well, i.e., the absorbance of the solution after the sample reacts with DPPH; T0—Sample background absorbance; C—The average of three absorbance values ​​from the solvent reaction well, i.e., the absorbance of the DPPH solution without sample added; C0 — Solvent background absorbance.

[0128] (2) Half-maximal clearance concentration (IC50 value): Plot a curve with the concentration of the test sample on the x-axis and the corresponding DPPH clearance rate on the y-axis, and fit the curve to obtain the regression equation (R²). 2 (≥0.9). Based on the regression equation, calculate the sample concentration corresponding to a DPPH clearance rate of 50%, which is the IC50 value of the test sample.

[0129] 6. Verification of experimental validity A positive control test must be added to each batch of experiments. The IC50 of the positive control vitamin E (the sample concentration at which 50% clearance is achieved) should be between 0.02 mg / mL and 0.06 mg / mL, or the clearance rate of the positive control vitamin E at a concentration of 0.06 mg / mL should be ≥50% for the test system to be considered effective.

[0130] The free radical scavenging rate of the sample at each test concentration is calculated according to formula (1). At the same time, the standard deviation SD between parallel wells in each group is calculated. If the SD value is ≤3%, the parallelism of the test is considered to be valid.

[0131] 7. Results Report When comparing the free radical scavenging activities between samples, a concentration-response curve can be plotted between the tested sample concentration and the DPPH free radical scavenging rate, and the fitting formula (R²) can be applied. 2 (≥0.9) Calculate the IC50 of each sample. The smaller the IC50 of a sample, the stronger its activity.

[0132] 8. Basis Shanghai Daily Chemicals Industry Association Group Standard T / SHRH 006-2018 "Cosmetics - Test Method for Free Radical (DPPH) Scavenging".

[0133] 9. Results The results are shown in Table 6.

[0134] Table 6: IC50 Results of DPPH Free Radical Scavenging Rate

[0135] 10. Conclusion (1) The human-like exosome composition provided by the present invention has excellent DPPH free radical scavenging activity and excellent antioxidant properties.

[0136] (2) Compared with one or two of human-like exosomes, rare ginsenoside CK and glycyrrhizin, the human-like exosome composition provided by the present invention contains human-like exosomes, rare ginsenoside CK and glycyrrhizin at the same time. When the three are present at the same time, they have a synergistic effect on antioxidant properties, which has an unexpected synergistic effect.

[0137] (3) Compared with one or two of human-like exosomes, rare ginsenoside CK and glycyrrhizin, the human-like exosome composition provided by the present invention contains human-like exosomes, rare ginsenoside CK and glycyrrhizin at the same time. When the three are present at the same time, they synergistically enhance each other, greatly improve the stability of the antioxidant properties of the obtained human-like exosome composition, and have unexpected synergistic effects.

[0138] (4) Compared with other active ingredients (such as ginsenoside Rg3 or retinol), the present invention preferably uses rare ginsenoside CK, which is more conducive to improving the antioxidant properties and stability of the obtained human-like exosome composition, and has unexpected technical effects.

[0139] (5) Compared with other active ingredients (such as resveratrol or glutathione), the present invention preferably uses glycyrrhizin, which is more conducive to improving the antioxidant properties and stability of the obtained human-like exosome composition, and has unexpected technical effects.

[0140] Experimental Example 3: Antioxidant Efficacy Assessment - In Vitro Fibroblast Reactive Oxygen Species (ROS) Content Test The cosmetic compositions described in the above embodiments were used to test the in vitro fibroblast reactive oxygen species (ROS) inhibition rate according to the following methods.

[0141] 1. Definition / Abbreviation DPBS: Duchenne phosphate buffer FBS: Fetal bovine serum MTT: 3-(4,5-dimethylthiazol-2)-2,5-diphenyltetrazolium bromide, also known as: thiazolium blue DMSO: Dimethyl sulfoxide VC: L-Ascorbic Acid DCFH-DA: 2',7'-Dichlorofluorescein diacetate ROS: Reactive Oxygen Species 2. Principle 2',7'-Dichlorodi-hydrofluoresceindiacetate (DCFH-DA) is non-fluorescent and can freely cross the cell membrane. Once inside the cell, it is hydrolyzed by esterases to form DCFH, which, unable to penetrate the cell membrane, accumulates intracellularly. Intracellular reactive oxygen species (ROS) oxidize the non-fluorescent DCFH to produce fluorescent DCF. The intensity of green fluorescence is directly proportional to the level of ROS within the cell. Hydrogen peroxide (H₂O₂), ultraviolet light, and blue light, as exogenous oxidants, can induce an increase in intracellular ROS levels. By comparing the changes in fluorescence intensity of the intracellular fluorescent dye DCFH-DA after administration of the negative control and the test substance, the relative fluorescence intensity and inhibition rate of ROS were calculated.

[0142] 3. Procedure 3.1 Equipment and Consumables: CO2 incubator, biosafety cabinet, inverted phase-contrast microscope, fluorescence microscope, autoclave, ELISA reader, cell counter, 12-well cell culture plate, pipettes 3.2 Solution reagents: (1) Complete culture medium: commercial culture medium + 15% FBS + 1% antibiotics (2) VC stock solution: Weigh a certain amount of L-ascorbic acid and dissolve it in the complete culture medium to prepare a stock solution of 10 mg / ml. Filter it with a 0.22 μm filter to remove bacteria and store it at -20 ℃. Avoid repeated freezing.

[0143] (3) Positive control: Take a certain amount of VC stock solution and dilute it with complete culture medium to make a working solution of 0.3 mg / ml. Prepare and use immediately.

[0144] 3.3 Experimental Methods (1) Sample processing The samples were diluted with cell culture medium to create multi-level concentration gradient samples; the samples were first diluted to a high concentration, sterilized by a sterilization filter, and then diluted to the working concentration (2wt%).

[0145] (2) Experimental steps Cell passage culture The cells are revived and cultured.

[0146] Cell proliferation rate assay Cytotoxicity experiments were conducted, and appropriate sample concentrations were selected based on the toxicity results to determine the content of reactive oxygen species (ROS) in cells.

[0147] Cell seeding plate Cells in the logarithmic growth phase were selected, digested with trypsin, and collected to form a cell suspension. Cells were then counted using a cell counter. The cells were diluted with cell culture medium to a suitable seeding density (70%–80% confluence 24 h after seeding) and seeded into 12-well plates at a volume of 1 ml per well. After seeding, the plates were incubated in a CO2 incubator for 24 h ± 2 h.

[0148] Cellular UVA modeling Discard the culture medium from the cell culture plate, add 0.5 mL of DPBS to each well, and irradiate with UVA. Except for the blank control wells or solvent control wells, all other sample wells, positive control wells (PC), and model wells (M) are irradiated with the same UVA dose (20 J / cm²). 2 After irradiation, the cell plate is transferred to a biosafety cabinet for sample loading.

[0149] Cell sampling Discard the DPBS solution in the cell culture plate and proceed with the drug administration. Add complete culture medium containing different concentrations of the sample to the sample group wells, add complete culture medium containing the positive control to the positive control wells, add complete culture medium / complete culture medium containing solvent to the blank / solvent control wells, and add complete culture medium or complete culture medium containing solvent to the model group. The sample volume per well is 1 ml. After drug administration, place the cell culture plate in a CO2 incubator and incubate for 1 h ± 15 min.

[0150] Cell-loaded probes After incubation, the DCFH-DA dye was diluted 1:1000 with serum-free medium to prepare the DCFH-DA dye working solution according to the instructions of the reactive oxygen species (ROS) assay kit. The culture medium in the culture plate was discarded, the plate was washed once with DPBS, and 1 ml of DCFH-DA dye working solution was added to each well. The plate was then incubated in the dark for 20 min.

[0151] ROS content detection After incubation, cells in each well were washed three times with DPBS. 150 μL of DPBS and 1.5 μL of hoechst 33342 nuclear dye were added to each well. The cell plate was transferred to a dark room and photographed using a fluorescence microscope (four different fields of view were selected from each well for ROS fluorescence and nuclear imaging). DCFH-DA was excited with blue fluorescence, and hoechst 33342 was excited with a UV laser. The acquired images were analyzed for fluorescence intensity using ImageJ software.

[0152] 4. Result Calculation 4.1 Formula for calculating absolute fluorescence intensity of ROS ROS absolute fluorescence intensity = average ROS fluorescence intensity / average nuclear fluorescence intensity 4.2 Formula for Calculating ROS Relative Fluorescence Intensity ROS relative fluorescence intensity (%) = T / C × 100%. ......... (1) (1) In the formula: T—Absolute fluorescence intensity of ROS in the test sample; C—The average of three absolute fluorescence intensities of ROS in the negative control.

[0153] 4.3 Formula for calculating ROS inhibition rate Inhibition rate (%) = (1-T / C) × 100%......... (2) (2) Where: T—The average of three relative fluorescence intensities of ROS in the test sample; C—The average of three relative fluorescence intensities of the negative control ROS.

[0154] 5. Verification of experimental validity 5.1 Validity Each batch of tests should include a positive control, which must demonstrate an inhibitory effect on ROS production in each batch, and be consistent with the negative control. If there is a significant difference compared to the control, the experimental system is considered effective.

[0155] 5.2 Parallelism The experiment requires statistical analysis of fluorescence intensity in images from four different fields of view for each experimental group, and calculation of the standard deviation (SD) of fluorescence intensity in the four different fields of view. After removing the image with the greatest difference, the coefficient of variation (CV) of relative fluorescence intensity in the remaining three images from different fields of view is calculated. If the CV value is ≤20%, the experiment is considered to be valid for parallelism.

[0156] 6. Results Report To evaluate the ability of a test substance to inhibit ROS, the inhibition rate of the test substance must be positive, and the fluorescence intensity value must be significantly different from that of the negative control (P<0.05).

[0157] 7. Results The results are shown in Table 7.

[0158] Table 7: ROS inhibition rate results

[0159] 8. Conclusion The human-like exosome composition provided by this invention has excellent ROS inhibition ability and excellent antioxidant properties.

[0160] The method of this invention has been described through preferred embodiments. Those skilled in the art will readily be able to modify or appropriately alter and combine the methods and applications described herein within the scope, spirit, and context of this invention to implement and apply the technology of this invention. Those skilled in the art can refer to the content herein to appropriately improve process parameters. It should be particularly noted that all similar substitutions and modifications are obvious to those skilled in the art and are considered to be included within the scope of this invention.

Claims

1. A human-like exosome composition, characterized in that, The human-like exosome composition comprises: human-like exosomes, a first active ingredient, and a solvent; the solvent comprises a first polyol; the first active ingredient comprises rare ginsenoside CK and glabridin; The weight ratio of the human-like exosomes and the rare ginsenoside CK is 100:0.4-100:3; The weight ratio of the human-like exosomes and the glabridin is 100:0.2-100:2.4; The weight ratio of the glabridin and the solvent is (0.2-2.4):(40-500).

2. The human-like exosome composition of claim 1, wherein the human-like exosomes are prepared from components of hydrogenated lecithin, phytosphingosine, cholesterol, ceramide, squalane, sodium stearoyl glutamate, a surface modification structure, a second polyol, a second active ingredient, and water.

3. The human-like exosome composition of any one of claims 1-2, wherein the preparation method of the human-like exosomes comprises the following steps: (1) Preparation of an alcohol phase: hydrogenated lecithin, phytosphingosine, cholesterol, ceramide, squalane, sodium stearoyl glutamate, a surface modification structure, and a second polyol are mixed to obtain an alcohol phase; (2) Preparation of an aqueous phase: a second active ingredient and water are mixed to obtain an aqueous phase; (3) Preparation of a mixed solution: the aqueous phase obtained in step (2) is added to the alcohol phase obtained in step (1), stirred, and homogenized to obtain a mixed solution; (4) Ultrasonic, high-pressure homogenization or membrane extrusion treatment: the mixed solution obtained in step (3) is subjected to ultrasonic, high-pressure homogenization or membrane extrusion treatment to obtain the human-like exosomes; The surface modification structure comprises a targeting peptide; the targeting peptide comprises cyclo-tetrapeptide-24 aminocyclohexanecarboxylate; The weight ratio of the hydrogenated lecithin and the phytosphingosine is (3-7):(0.03-0.1); The weight ratio of the hydrogenated lecithin and the cholesterol is (3-7):(0.3-1); The weight ratio of the hydrogenated lecithin and the ceramide is (3-7):(0.005-0.04); The weight ratio of the hydrogenated lecithin and the squalane is (3-7):(0.05-0.2); The weight ratio of the hydrogenated lecithin and the sodium stearoyl glutamate is (3-7):(0.2-0.8); The weight ratio of the hydrogenated lecithin and the second polyol is (3-7):(7-30); The weight ratio of the hydrogenated lecithin and the surface modification structure is (3-7):(0.001-0.05); The weight ratio of the second polyol and the water is (7-30):(19.2-85.1); The weight ratio of the second active ingredient and the water is (0.61-51.52):(19.2-85.1).

4. The human-like exosome composition of any one of claims 1-3, wherein the preparation method of the human-like exosome composition comprises: Mixing the rare ginsenoside CK and the glabridin with the solvent to obtain a mixed solution A, and then mixing the mixed solution A with the human-like exosomes to obtain the human-like exosome composition.

5. The human-like exosome composition according to any one of claims 1-4, wherein the second active ingredient comprises at least one of arginine / lysine polypeptide solution, PDRN, miRNA, mixed amino acids, nicotinamide adenine dinucleotide; and / or the first polyol and the second polyol are independently selected from at least one of 1,3-butanediol, 1,3-propanediol, glycerol, 1,2-hexanediol, ethoxydiglycol; and / or the content of the hydrogenated lecithin is 3wt%-7wt%, the content of the phytosphingosine is 0.03wt%-0.1wt%, the content of the cholesterol is 0.3wt%-1wt%, the content of the ceramide is 0.005wt%-0.04wt%, the content of the squalane is 0.05wt%-0.2wt%, the content of the sodium stearoyl glutamate is 0.2wt%-0.8wt%, the content of the second polyol is 7wt%-30wt%, the content of the surface modification structure is 0.001wt%-0.05wt%, the content of the second active ingredient is 0.61wt%-51.52wt%, and the content of the water is 19.2wt%-85.1wt%, based on the total weight of the human-like exosome.

6. The human-like exosome composition according to claim 3, wherein the pressure of the high-pressure homogenization in step (4) is 1500-2000 bar. The number of cycles of the high-pressure homogenization in step (4) is 4-6 times. The temperature of the high-pressure homogenization in step (4) is 10℃-25℃. Comprising: mixing the rare ginsenoside CK and glabridin with the solvent to obtain a mixed solution A, and then mixing the mixed solution A with the human-like exosome to obtain the human-like exosome composition human-like.

7. A method of producing the human-like exosome composition of any one of claims 1-6, wherein the method comprises, 8. Use of the human-like exosome composition according to any one of claims 1-6 or prepared by the preparation method of claim 7 in the preparation of a cosmetic product. Optionally, the cosmetic product is used for antioxidant. Comprising the human-like exosome composition according to any one of claims 1-6 or prepared by the preparation method of claim 7.

10. The cosmetic product according to claim 9, wherein the cosmetic product is used for antioxidant.

9. A cosmetic product, characterized by, ​ ​

Images